
HROW Stock Forecast & Price Target
HROW Analyst Ratings
Bulls say
Harrow is expected to experience significant growth in the coming years due to its strong portfolio of branded ophthalmic pharmaceuticals and continuous investment in R&D to address unmet needs in the eye care market. The recent launch of BYOOVIZ and the successful acquisition of a biosimilar product referencing LUCENTIS reflect the company's strategic focus on innovation and expansion. Despite potential risks, Harrow's strong reputation and partnerships in the industry position them well for continued growth.
Bears say
Harrow is poised for growth with the launch of new products such as Byqlovi and Byooviz in 3Q26 and expected revenue of $350M-$365M in 2026. However, concerns about potential safety issues with IHEEZO may dampen investor confidence. Additionally, an increasing reliance on acquisitions to drive growth raises questions about the sustainability of the company's growth strategy.
This aggregate rating is based on analysts' research of Harrow Health Inc and is not a guaranteed prediction by Public.com or investment advice.
HROW Analyst Forecast & Price Prediction
Start investing in HROW
Order type
Buy in
Order amount
Est. shares
0 shares